Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Diagnostics › Molecular Diagnostics › GeneCapture To Enter Point of Care MDx Market With Affordable Infectious Disease Screening Platform

GeneCapture To Enter Point of Care MDx Market With Affordable Infectious Disease Screening Platform

Apr 27, 2018
|
John Gilmore
Premium

NEW YORK (GenomeWeb) – Startup GeneCapture has announced that it plans to enter the point of care diagnostics market by screening for common infectious diseases in vulnerable areas with its portable genotyping platform.

Based in Huntsville, Alabama, GeneCapture spun out of the University of Alabama at Huntsville (UAH) in 2009 as a partnership between CEO Peggy Sammon and CTO Krishnan Chittur. Chittur previously developed the original gene probe technology underlying GeneCapture's platform at UAH and later applied for a patent.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Jul
14
Featured Webinar

Development of a Metagenomics-based Pathogen-Detection Assay for SARS-CoV-2 Research

This webinar will describe a rapid metagenomics assay under development for human pathogens, including the SARS-CoV-2 coronavirus.

Jul
15
Featured Webinar

Diagnostic Challenges in Cancer Immunotherapy: An Expert Panel Discussion

Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.

Jul
23
Featured Webinar

Clinical Utility of Liquid Biopsy for the Detection of T790M to Guide Lung Cancer Treatment Strategy

This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.

What's Popular?

In Molecular Diagnostics

  1. FDA Letter Warns About False-Positive Results From Becton Dickinson SARS-CoV-2 Test

  2. Thermo Fisher Scientific, First Genetics to Develop NGS-Based Diagnostics in Russia

  3. FDA Grants EUA for UCSF, Broad Institute, BioSewoom Coronavirus Tests

  4. SARS-CoV-2 Pandemic May Promote Progress in Paper MDx

    Premium

  5. Vela Diagnostics Automated Coronavirus Test Gets CE-IVD Mark

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.